Potent Inhibition of Hendra Virus Infection Via RNA Interference and Poly I:C Immune Activation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 May 22

PMID 23691205

Citations 3

Authors

Jana L McCaskill

Glenn A Marsh

Paul Monaghan

Lin-Fa Wang

Timothy Doran

Nigel A J McMillan

Affiliations

Soon will be listed here.

Abstract

Hendra virus (HeV) is a highly pathogenic zoonotic paramyxovirus that causes fatal disease in a wide range of species, including humans. HeV was first described in Australia in 1994, and has continued to re-emerge with increasing frequency. HeV is of significant concern to human health due to its high mortality rate, increasing emergence, absence of vaccines and limited post exposure therapies. Here we investigate the use of RNA interference (RNAi) based therapeutics targeting HeV in conjunction with the TLR3 agonist Poly I:C and show that they are potent inhibitors of HeV infection in vitro. We found that short interfering RNAs (siRNAs) targeting the abundantly expressed N, P and M genes of HeV caused over 95% reduction of HeV virus titre, protein and mRNA. Furthermore, we found that the combination of HeV targeting siRNA and Poly I:C had an additive effect in suppressing HeV infection. Our results demonstrate for the first time that RNAi and type I interferon stimulation are effective inhibitors of HeV replication in vitro and may provide an effective therapy for this highly lethal, zoonotic pathogen.

Citing Articles

Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection.

Supramaniam A, Tayyar Y, Clarke D, Kelly G, Acharya D, Morris K J Microbiol Immunol Infect. 2023; 56(3):516-525.

PMID: 36934064 PMC: 9991324. DOI: 10.1016/j.jmii.2023.02.010.

Polymers in the Delivery of siRNA for the Treatment of Virus Infections.

Reynolds N, Dearnley M, Hinton T Top Curr Chem (Cham). 2017; 375(2):38.

PMID: 28324594 PMC: 7100576. DOI: 10.1007/s41061-017-0127-6.

Coxsackievirus cloverleaf RNA containing a 5' triphosphate triggers an antiviral response via RIG-I activation.

Feng Q, Langereis M, Olagnier D, Chiang C, van de Winkel R, van Essen P PLoS One. 2014; 9(4):e95927.

PMID: 24759703 PMC: 3997492. DOI: 10.1371/journal.pone.0095927.

References

Boden D, Pusch O, Lee F, Tucker L, Ramratnam B . Human immunodeficiency virus type 1 escape from RNA interference. J Virol. 2003; 77(21):11531-5. PMC: 229317. DOI: 10.1128/jvi.77.21.11531-11535.2003. View

Burnett J, Rossi J, Tiemann K . Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J. 2011; 6(9):1130-46. PMC: 3388104. DOI: 10.1002/biot.201100054. View

Virtue E, Marsh G, Wang L . Interferon signaling remains functional during henipavirus infection of human cell lines. J Virol. 2011; 85(8):4031-4. PMC: 3126122. DOI: 10.1128/JVI.02412-10. View

Selvey L, Wells R, McCormack J, Ansford A, Murray K, Rogers R . Infection of humans and horses by a newly described morbillivirus. Med J Aust. 1995; 162(12):642-5. DOI: 10.5694/j.1326-5377.1995.tb126050.x. View

Matsumoto M, Seya T . TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev. 2008; 60(7):805-12. DOI: 10.1016/j.addr.2007.11.005. View

Shaw M, Garcia-Sastre A, Palese P, Basler C . Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol. 2004; 78(11):5633-41. PMC: 415790. DOI: 10.1128/JVI.78.11.5633-5641.2004. View

Gish R, Satishchandran C, Young M, Pachuk C . RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study. Antivir Ther. 2011; 16(4):547-54. DOI: 10.3851/IMP1798. View

Rodriguez J, Horvath C . Host evasion by emerging paramyxoviruses: Hendra virus and Nipah virus v proteins inhibit interferon signaling. Viral Immunol. 2004; 17(2):210-9. DOI: 10.1089/0882824041310568. View

Park M, Shaw M, Munoz-Jordan J, Cros J, Nakaya T, Bouvier N . Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol. 2002; 77(2):1501-11. PMC: 140815. DOI: 10.1128/jvi.77.2.1501-1511.2003. View

10.

Gurley E, Montgomery J, Hossain M, Bell M, Azad A, Islam M . Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis. 2008; 13(7):1031-7. PMC: 2878219. DOI: 10.3201/eid1307.061128. View

11.

Broder C . Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr Opin Virol. 2012; 2(2):176-87. PMC: 4347837. DOI: 10.1016/j.coviro.2012.02.016. View

12.

Bossart K, Geisbert T, Feldmann H, Zhu Z, Feldmann F, Geisbert J . A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med. 2011; 3(105):105ra103. PMC: 3313625. DOI: 10.1126/scitranslmed.3002901. View

13.

Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K . Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med. 2008; 205(7):1601-10. PMC: 2442638. DOI: 10.1084/jem.20080091. View

14.

Mungall B, Schopman N, Lambeth L, Doran T . Inhibition of Henipavirus infection by RNA interference. Antiviral Res. 2008; 80(3):324-31. PMC: 7125758. DOI: 10.1016/j.antiviral.2008.07.004. View

15.

Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell R . Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A. 2006; 103(22):8459-64. PMC: 1464000. DOI: 10.1073/pnas.0603082103. View

16.

Wright P, Crameri G, Eaton B . RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcription. Arch Virol. 2004; 150(3):521-32. DOI: 10.1007/s00705-004-0417-5. View

17.

Crameri G, Wang L, Morrissy C, White J, Eaton B . A rapid immune plaque assay for the detection of Hendra and Nipah viruses and anti-virus antibodies. J Virol Methods. 2001; 99(1-2):41-51. DOI: 10.1016/s0166-0934(01)00377-9. View

18.

Luby S, Rahman M, Hossain M, Blum L, Husain M, Gurley E . Foodborne transmission of Nipah virus, Bangladesh. Emerg Infect Dis. 2007; 12(12):1888-94. PMC: 3291367. DOI: 10.3201/eid1212.060732. View

19.

Buti M, Esteban R . 1990-2010: two decades of interferon-based therapy. Clin Liver Dis. 2011; 15(3):473-82. DOI: 10.1016/j.cld.2011.05.007. View

20.

Tulac S, Dosiou C, Suchanek E, Giudice L . Silencing lamin A/C in human endometrial stromal cells: a model to investigate endometrial gene function and regulation. Mol Hum Reprod. 2004; 10(10):705-11. DOI: 10.1093/molehr/gah105. View